Natixis Grifols Sa Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$17.44 - $21.53 $25.9 Million - $32 Million	-1,484,482 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.97 - $21.96 $208,327 - $229,086	10,432 Added 0.71%	1,484,482 $31.7 Million
Q2 2018 Aug 14, 2018	SELL	$20.16 - $24.68 $30.3 Million - $37.1 Million	-1,501,363 Reduced 50.46%	1,474,050 $31.7 Million
Q1 2018 May 15, 2018	BUY	$20.31 - $24.95 $60.4 Million - $74.2 Million	2,975,413 New	2,975,413 $68.5 Million
Q4 2017 Feb 14, 2018	SELL	$20.99 - $23.89 $41.5 Million - $47.2 Million	-1,975,528 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$20.07 - $21.89 $11,379 - $12,411	-567 Reduced 0.03%	1,975,528 $43.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,976,095	1,976,095 $41.8 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.